{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:38:22Z","timestamp":1786977502027,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T00:00:00Z","timestamp":1233705600000},"content-version":"vor","delay-in-days":4662,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[1996,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Background:<\/jats:italic>\n                    Pharmacological conversion of paroxysmal atrial fibrillation is frequently necessary. The aim of this study was to compare intravenous propafenone, a class Ic antiar\u2010rhythmic agent, with placebo in paroxysmal atrial fibrillation (AF) of recent onset (&lt;72 h).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Patients and methods:<\/jats:italic>\n                    We randomly allocated 75 patients, aged 18 to 70 years, with paroxysmal AF to receive intravenous propafenone (2 mg\/kg in 15 min followed by 1 mg\/kg in 2 h) or the matching placebo. Patients were followed for 3 h. Exclusion criteria were the presence of one of the following: clinical heart failure, recent acute myocardial infarction, hypotension, atrioventricular block, Wolff\u2010Parkinson\u2010White syndrome, or current treatment with antiarrhythmic agents or digitalis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results:<\/jats:italic>\n                    No sign of heart disease was found in 74.7% of the patients. Echocardiographically determined left atrium diameter was similar in the two groups. Conversion to sinus rhythm occurred in 24 of 41 patients allocated to propafenone and in 10 of 34 patients allocated to placebo (odds ratio 3.2, 95% confidence intervals 1.3\u20107.9;p&lt;0.01). Mean conversion time was 34 \u00b1 29 and 71 \u00b1 55 min, respectively, for propafenone and placebo. Mean heart rate in nonconverters decreased from 146 to 109 beats\/min in patients treated with propafenone while it remained virtually unchanged in those treated with placebo. Only minor side effects were noted.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions:<\/jats:italic>\n                    Intravenous propafenone is an effective therapeutic option for restoring sinus rhythm in patients with paroxysmal AF of recent onset.\n                  <\/jats:p>","DOI":"10.1002\/clc.4960190515","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T03:04:07Z","timestamp":1233716647000},"page":"409-412","source":"Crossref","is-referenced-by-count":49,"title":["Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo\u2010controlled, double\u2010blind, multicenter clinical trial"],"prefix":"10.1002","volume":"19","author":[{"given":"Claudio","family":"Fresco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Proclemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Buia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Morgera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)\u20102 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/jama.1981.03310400022019","article-title":"Mortality in an insured population with atrial fibrillation","volume":"245","author":"Gajewski J","year":"1981","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_3_2","first-page":"622","article-title":"Embolic complications in paroxysmal atrial fibrillation","volume":"19","author":"Petersen P","year":"1988","journal-title":"Stroke"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03029730"},{"issue":"1","key":"e_1_2_1_5_2","first-page":"664","article-title":"On behalf of the PAFIT\u20101 Group: Safety and efficacy of propafenone i.v. in conversion of paroxysmal atrial fibrillation of recent onset","volume":"86","author":"Bracchetti D","year":"1992","journal-title":"Circulation"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.5.1038"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90326-K"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(88)90511-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-2-141"},{"key":"e_1_2_1_10_2","first-page":"164","article-title":"Conversion of recent onset atrial fibrillation: A controlled study on 163 patients evaluating the efficacy of a single oral loading dose of propafenone or flecainide (abstr)","volume":"14","author":"Capucci A","year":"1993","journal-title":"Eur Heart J"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90049-0"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-539"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908103210629"},{"key":"e_1_2_1_14_2","first-page":"333","volume-title":"Prognosis and Risk Assessment in Cardiovascular Disease","author":"Farahi JJ","year":"1993"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960190515","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.4960190515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T14:11:33Z","timestamp":1698415893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960190515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,5]]}},"alternative-id":["10.1002\/clc.4960190515"],"URL":"https:\/\/doi.org\/10.1002\/clc.4960190515","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,5]]}}}